JP2025521085A5 - - Google Patents

Info

Publication number
JP2025521085A5
JP2025521085A5 JP2024566272A JP2024566272A JP2025521085A5 JP 2025521085 A5 JP2025521085 A5 JP 2025521085A5 JP 2024566272 A JP2024566272 A JP 2024566272A JP 2024566272 A JP2024566272 A JP 2024566272A JP 2025521085 A5 JP2025521085 A5 JP 2025521085A5
Authority
JP
Japan
Prior art keywords
antibody
antibody according
seq
human
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024566272A
Other languages
English (en)
Japanese (ja)
Other versions
JP7801491B2 (ja
JP2025521085A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/062545 external-priority patent/WO2023217933A1/en
Publication of JP2025521085A publication Critical patent/JP2025521085A/ja
Publication of JP2025521085A5 publication Critical patent/JP2025521085A5/ja
Priority to JP2026000410A priority Critical patent/JP2026062918A/ja
Application granted granted Critical
Publication of JP7801491B2 publication Critical patent/JP7801491B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024566272A 2022-05-11 2023-05-11 Vegf-aおよびil6に結合する抗体ならびに使用方法 Active JP7801491B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026000410A JP2026062918A (ja) 2022-05-11 2026-01-05 Vegf-aおよびil6に結合する抗体ならびに使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22172759.7 2022-05-11
EP22172759 2022-05-11
PCT/EP2023/062545 WO2023217933A1 (en) 2022-05-11 2023-05-11 Antibody that binds to vegf-a and il6 and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026000410A Division JP2026062918A (ja) 2022-05-11 2026-01-05 Vegf-aおよびil6に結合する抗体ならびに使用方法

Publications (3)

Publication Number Publication Date
JP2025521085A JP2025521085A (ja) 2025-07-08
JP2025521085A5 true JP2025521085A5 (cg-RX-API-DMAC10.html) 2025-12-02
JP7801491B2 JP7801491B2 (ja) 2026-01-16

Family

ID=81603574

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024566272A Active JP7801491B2 (ja) 2022-05-11 2023-05-11 Vegf-aおよびil6に結合する抗体ならびに使用方法
JP2026000410A Pending JP2026062918A (ja) 2022-05-11 2026-01-05 Vegf-aおよびil6に結合する抗体ならびに使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026000410A Pending JP2026062918A (ja) 2022-05-11 2026-01-05 Vegf-aおよびil6に結合する抗体ならびに使用方法

Country Status (16)

Country Link
US (1) US20250163139A1 (cg-RX-API-DMAC10.html)
EP (1) EP4522648A1 (cg-RX-API-DMAC10.html)
JP (2) JP7801491B2 (cg-RX-API-DMAC10.html)
KR (1) KR20250008903A (cg-RX-API-DMAC10.html)
CN (1) CN119173529A (cg-RX-API-DMAC10.html)
AR (1) AR129268A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023267952A1 (cg-RX-API-DMAC10.html)
CA (1) CA3256863A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024003373A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024015714A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240473A (cg-RX-API-DMAC10.html)
IL (1) IL316326A (cg-RX-API-DMAC10.html)
MX (1) MX2024013703A (cg-RX-API-DMAC10.html)
PE (1) PE20251283A1 (cg-RX-API-DMAC10.html)
TW (1) TW202402810A (cg-RX-API-DMAC10.html)
WO (1) WO2023217933A1 (cg-RX-API-DMAC10.html)

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
ATE297452T1 (de) 1998-07-23 2005-06-15 Avebe Coop Verkoop Prod Klebemittelzusammensetzung
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
WO2007104529A2 (en) * 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
PT2600812T (pt) 2010-08-05 2021-11-09 Forsight Vision4 Inc Aparelho para tratar um olho
AU2011285637B2 (en) 2010-08-05 2014-10-30 Forsight Vision4, Inc. Subconjunctival implant for posterior segment drug delivery
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
SG195196A1 (en) 2011-05-27 2013-12-30 Dutalys Dual targeting
ES2864203T3 (es) 2011-09-16 2021-10-13 Forsight Vision4 Inc Aparato de intercambio de fluido
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
KR102069397B1 (ko) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Fc-수용체 기재 친화성 크로마토그래피
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
US20160302965A1 (en) 2013-12-06 2016-10-20 Forsight Vision4, Inc. Implantable therapeutic devices
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
JP7674383B2 (ja) 2020-03-30 2025-05-09 エフ. ホフマン-ラ ロシュ アーゲー Vegf及びpdgf-bに結合する抗体及び使用方法

Similar Documents

Publication Publication Date Title
JP2023538891A5 (cg-RX-API-DMAC10.html)
CN102421795B (zh) 针对肌钙蛋白i的抗体及其使用方法
JP2021526022A5 (cg-RX-API-DMAC10.html)
HRP20251181T1 (hr) Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene
IL261673A (en) Protein-like binding proteins with a double variable region have a cross-linking region direction
CN115461368A (zh) 抗人白细胞介素-4受体α抗体及其制备方法和应用
HRP20171765T1 (hr) Protutijela koja vežu il-4 i/ili il-13 i njihova uporaba
JP2024105229A5 (cg-RX-API-DMAC10.html)
RU2008126948A (ru) Связывающие полипептиды и их применения
JP2018527952A5 (cg-RX-API-DMAC10.html)
JP2025067915A5 (cg-RX-API-DMAC10.html)
JP2021524275A5 (cg-RX-API-DMAC10.html)
JP2014526898A5 (cg-RX-API-DMAC10.html)
JP2016503412A5 (ja) Il−6アンタゴニストおよびその使用
FI3797121T3 (fi) Cd3:lle spesifisiä vasta-aineita ja niiden käyttöjä
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
JP2020537520A5 (cg-RX-API-DMAC10.html)
JP2019509054A5 (cg-RX-API-DMAC10.html)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
HRP20191590T1 (hr) Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen
JP2023524643A5 (cg-RX-API-DMAC10.html)
CN105229036A (zh) 在疏水性相互作用位点内引入了静电相互作用的蛋白及其制备方法
RU2013126025A (ru) Коллекция и способы ее применения
JP2023516925A5 (cg-RX-API-DMAC10.html)
JP2023506834A5 (cg-RX-API-DMAC10.html)